Navigation Links
NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development

NEW YORK, March 7, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce that Jason Kolbert has joined the firm as Vice President of Strategic Business Development. Jason was formerly a managing director of National Securities where he founded the firm's research effort in emerging biotechnology companies. Jason's coverage universe has been focused on cell therapeutic companies focused in oncology and regenerative medicine, where NeoStem was one of his covered companies.

Jason has spent the past 16 years on Wall Street as an analyst both managing biotechnology dedicated investments (buy-side) and covering biotechnology companies (sell-side). Prior to his career on Wall Street he spent several years in the pharmaceutical industry with Schering-Plough in Japan where he developed an extensive working knowledge of pharmaceutical operations in Asia. Jason has an undergraduate degree in Chemistry (New Paltz) and an MBA in Finance (University of New Haven).

"NeoStem represents everything my training has taught me to look for: a highly experienced management team with an established track record, a promising core technology (VSEL™ Technology) with an active research facility that holds great clinical promise, and expertise in complex biologic manufacturing coupled with revenues and extensive client relationships (Progenitor Cell Therapy), all combined with a separate business line in pharmaceutical API manufacturing (Suzhou Erye) that has significant  revenues from one of the most attractive and growing regions of the world - China. All of the assets are here and, with some strategic focus, I believe we can both unlock value for shareholders and change people's lives as the medical paradigm shifts to cell-based approaches," said Jason Kolbert, Vice President of Strategic Business Development.

Dr. Robin L. Smith, Chairman and CEO of NeoStem, said, "Jason's working knowledge of the biotechnology industry and experience in Asia coupled with his background in finance and established track record on Wall Street come to NeoStem at a critical time in our growth.  We look forward to working with Jason to capitalize on our business initiatives as the company continues to evolve into a fully integrated biotechnology company developing new therapeutics and a strong product pipeline supported with expanding product revenues, contract manufacturing, and a growing cell collection and storage business."

About NeoStem, Inc.NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company.  NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.  The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.

For more information, please visit:

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.  NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger.  Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: Web:

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
2. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
3. NeoStem Acquires Progenitor Cell Therapy
4. NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards
5. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
6. FOX Business Network Airing In-Depth Look at NeoStem
7. NeoStem to Present at Rodman & Renshaws 12th Annual Healthcare Conference
8. NeoStem Provides Second Quarter Update
9. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
10. NeoStem Named Best Stem Cell Company in The New Economys 2010 Biotech Awards
11. NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:10/29/2015)... MINNETONKA, Minn. , Oct. 29, 2015   ... that supports the entire spectrum of clinical research, is ... the Minnesota High Tech Association (MHTA) as one of ... in the "Software – Small and Growing" category. The ... and individuals who have shown superior technology innovation and ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):